NeoPharm Co (XKRX:092730) COGS-to-Revenue : 0.39 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is NeoPharm Co COGS-to-Revenue?

NeoPharm Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ₩10,936 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩28,215 Mil.

NeoPharm Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NeoPharm Co's Gross Margin % for the three months ended in Mar. 2024 was 61.24%.

NeoPharm Co COGS-to-Revenue Historical Data

The historical data trend for NeoPharm Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoPharm Co COGS-to-Revenue Chart

NeoPharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.29

0.31

0.33

NeoPharm Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.31	0.31	0.32	0.36	0.39

NeoPharm Co COGS-to-Revenue Calculation

NeoPharm Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	31719.585	/	97104.89
	=	0.33

NeoPharm Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	10936.204	/	28215.374
	=	0.39

NeoPharm Co (XKRX:092730) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NeoPharm Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	10936.204 / 28215.374
	=	61.24 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NeoPharm Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeoPharm Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoPharm Co (XKRX:092730) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » NeoPharm Co Ltd (XKRX:092730) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

928 Tamnip-dong, Yuseong-gu, Daejon, KOR, 305-510

Website

http://www.neopharm.co.kr

NeoPharm Co Ltd is a South Korean company operating in the household and personal products. The products of the company include skin care brand, skin barrier special dermo cosmetic brand, hospital functional products, and life moisturizing body professional brand.

NeoPharm Co (XKRX:092730) Headlines

No Headlines